Combining αB7-H3-αCD3 ENG T cells with multi-specific antibodies targeting antigens commonly found on MM cells—such as BCMA, CD38, and CD138—could further enhance treatment efficacy, though this hypothesis requires validation through in vitro and in vivo studies using MM cancer xenograft mouse models. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.